| http://dbpedia.org/ontology/abstract
|
レンボレキサント（Lemborexant）は、成人の入眠困難および睡眠維持困難を特徴とする不眠症の治療薬である。レンボレキサントは、2019年12月20日に不眠症の成人による使用がアメリカ合衆国で承認され、2020年1月23日には日本での使用が承認され、エーザイから商品名「デエビゴ」で発売されている。
, Lemborexant, sold under the brand name Day … Lemborexant, sold under the brand name Dayvigo, is an orexin antagonist medication which is used in the treatment of insomnia. It is indicated specifically for the treatment of insomnia characterized by difficulties with sleep onset and/or maintenance in adults. The medication is taken by mouth. Side effects of lemborexant include somnolence, fatigue, headache, and abnormal dreams. The medication is a dual orexin receptor antagonist (DORA). It acts as a selective dual antagonist of the orexin receptors OX1 and OX2. Lemborexant has a long elimination half-life of 17 to 55 hours and a time to peak of about 1 to 3 hours. It is not a benzodiazepine or Z-drug and does not interact with GABA receptors, instead having a distinct mechanism of action. Lemborexant was approved for medical use in the United States in December 2019. It is a schedule IV controlled substance in the United States and may have a low potential for misuse. Besides lemborexant, other orexin receptor antagonists including suvorexant and daridorexant have also been introduced.nd daridorexant have also been introduced.
, Lemborexant ist ein Arzneistoff zur Behandlung von Schlafstörungen. Lemborexant wurde von Eisai entwickelt und im Jahr 2019 unter dem Handelsnamen Dayvigo von der FDA zugelassen.
, Лемборексант — антагонист орексиновых рецепторов, используемый как снотворное средство. Одобрен для применения: США (2019), Япония (2020).
, Lemborexant, comercializado sob o nome com … Lemborexant, comercializado sob o nome comercial Dayvigo, é um medicamento antagonista da orexina utilizado no tratamento da insônia. É indicado especificamente para o tratamento da insônia caracterizada pela dificuldade de iniciar e/ou manter o sono em adultos. A medicação é tomada por via oral. Os efeitos colaterais do lemborexant incluem sonolência, fadiga, dor de cabeça e sonhos anormais. O medicamento é um duplo antagonista dos receptores de orexina (DORA). Atua como um antagonista dual e dos e . O lemborexant tem uma meia-vida longa de 17 a 55 horas e um atinge o pico de concentração em cerca de 1 a 3 horas. Não é um benzodiazepínico nem uma droga Z e, também, não interage com os receptores GABA, tendo um mecanismo de ação distinto. O lemborexant foi aprovado para uso médico nos Estados Unidos em dezembro de 2019. É uma substância controlada de receituário IV nos Estados Unidos, podendo ter um baixo risco para uso indevido. Além do lemborexant, outros antagonistas do receptor de orexina, incluindo suvorexant e , também foram introduzidos no mercado. e , também foram introduzidos no mercado.
|
| http://dbpedia.org/ontology/alternativeName
|
Dayvigo
|
| http://dbpedia.org/ontology/casNumber
|
1369764-02-2
|
| http://dbpedia.org/ontology/chEMBL
|
3545367
|
| http://dbpedia.org/ontology/class
|
http://dbpedia.org/resource/Orexin_antagonist +
|
| http://dbpedia.org/ontology/drugbank
|
DB11951
|
| http://dbpedia.org/ontology/fdaUniiCode
|
0K5743G68X
|
| http://dbpedia.org/ontology/kegg
|
D11022
|
| http://dbpedia.org/ontology/pubchem
|
56944144
|
| http://dbpedia.org/ontology/thumbnail
|
http://commons.wikimedia.org/wiki/Special:FilePath/Lemborexant_Structure.svg?width=300 +
|
| http://dbpedia.org/ontology/wikiPageExternalLink
|
https://druginfo.nlm.nih.gov/drugportal/name/lemborexant +
|
| http://dbpedia.org/ontology/wikiPageID
|
46784047
|
| http://dbpedia.org/ontology/wikiPageLength
|
21359
|
| http://dbpedia.org/ontology/wikiPageRevisionID
|
1105949600
|
| http://dbpedia.org/ontology/wikiPageWikiLink
|
http://dbpedia.org/resource/Generic_term +
, http://dbpedia.org/resource/Z-drug +
, http://dbpedia.org/resource/Metabolism +
, http://dbpedia.org/resource/Standardized_mean_difference +
, http://dbpedia.org/resource/Sluggishness +
, http://dbpedia.org/resource/Japan +
, http://dbpedia.org/resource/CYP3A4 +
, http://dbpedia.org/resource/Canada +
, http://dbpedia.org/resource/Category:Pyridines +
, http://dbpedia.org/resource/Network_meta-analysis +
, http://dbpedia.org/resource/CYP3A5 +
, http://dbpedia.org/resource/Efficacy +
, http://dbpedia.org/resource/Insomnia +
, http://dbpedia.org/resource/Category:Japanese_inventions +
, http://dbpedia.org/resource/Australia +
, http://dbpedia.org/resource/Hypnagogic_hallucination +
, http://dbpedia.org/resource/Systematic_review +
, http://dbpedia.org/resource/Orexin_antagonist +
, http://dbpedia.org/resource/Eisai_%28company%29 +
, http://dbpedia.org/resource/Attention +
, http://dbpedia.org/resource/Lethargy +
, http://dbpedia.org/resource/Orexin +
, http://dbpedia.org/resource/Somnolence +
, http://dbpedia.org/resource/Excretion +
, http://dbpedia.org/resource/Acceptability +
, http://dbpedia.org/resource/Tolerability +
, http://dbpedia.org/resource/Memory +
, http://dbpedia.org/resource/Category:Fluoroarenes +
, http://dbpedia.org/resource/Hypocretin_%28orexin%29_receptor_1 +
, http://dbpedia.org/resource/Sleep_apnea_syndrome +
, http://dbpedia.org/resource/Drug_tolerance +
, http://dbpedia.org/resource/Tmax_%28pharmacology%29 +
, http://dbpedia.org/resource/Liver +
, http://dbpedia.org/resource/Elimination_%28pharmacology%29 +
, http://dbpedia.org/resource/Effect_size +
, http://dbpedia.org/resource/Mechanism_of_action +
, http://dbpedia.org/resource/Tablet_%28pharmacy%29 +
, http://dbpedia.org/resource/Duration_of_action +
, http://dbpedia.org/resource/Clearance_%28pharmacology%29 +
, http://dbpedia.org/resource/Plasma_protein_binding +
, http://dbpedia.org/resource/Chronic_obstructive_pulmonary_disease +
, http://dbpedia.org/resource/Category:Carboxamides +
, http://dbpedia.org/resource/In_vitro +
, http://dbpedia.org/resource/Fatigue_%28medical%29 +
, http://dbpedia.org/resource/Oral_administration +
, http://dbpedia.org/resource/Category:Cyclopropanes +
, http://dbpedia.org/resource/Cmax_%28pharmacology%29 +
, http://dbpedia.org/resource/Controlled_Substances_Act +
, http://dbpedia.org/resource/Terminal_elimination_half-life +
, http://dbpedia.org/resource/Dual_orexin_receptor_antagonist +
, http://dbpedia.org/resource/Urine +
, http://dbpedia.org/resource/Film-coated +
, http://dbpedia.org/resource/European_Medicines_Agency +
, http://dbpedia.org/resource/Placebo +
, http://dbpedia.org/resource/Drug-liking +
, http://dbpedia.org/resource/Category:Organofluorides +
, http://dbpedia.org/resource/Phases_of_clinical_research +
, http://dbpedia.org/resource/Hypocretin_%28orexin%29_receptor_2 +
, http://dbpedia.org/resource/Sleep_paralysis +
, http://dbpedia.org/resource/Category:Orexin_antagonists +
, http://dbpedia.org/resource/Orexin_receptor +
, http://dbpedia.org/resource/Feces +
, http://dbpedia.org/resource/Benzodiazepine +
, http://dbpedia.org/resource/Clinical_trial +
, http://dbpedia.org/resource/Sleep_maintenance +
, http://dbpedia.org/resource/Misuse_potential +
, http://dbpedia.org/resource/Daridorexant +
, http://dbpedia.org/resource/Eszopiclone +
, http://dbpedia.org/resource/Headache +
, http://dbpedia.org/resource/Controlled_substance +
, http://dbpedia.org/resource/Abnormal_dream +
, http://dbpedia.org/resource/Nightmare +
, http://dbpedia.org/resource/Medicines_and_Healthcare_products_Regulatory_Agency +
, http://dbpedia.org/resource/Side_effect +
, http://dbpedia.org/resource/Elimination_half-life +
, http://dbpedia.org/resource/Receptor_antagonist +
, http://dbpedia.org/resource/GABA_receptor +
, http://dbpedia.org/resource/Effective_half-life +
, http://dbpedia.org/resource/Suvorexant +
, http://dbpedia.org/resource/Bioavailability +
, http://dbpedia.org/resource/File:Peak_normalized-concentrations_of_suvorexant_and_lemborexant_with_administration_at_steady_state_in_humans.png +
, http://dbpedia.org/resource/Sleep_onset +
, http://dbpedia.org/resource/European_Union +
, http://dbpedia.org/resource/Drug_dependence +
, http://dbpedia.org/resource/Binding_selectivity +
, http://dbpedia.org/resource/Category:Hypnotics +
, http://dbpedia.org/resource/United_Kingdom +
, http://dbpedia.org/resource/Circadian_rhythm_sleep_disorder +
, http://dbpedia.org/resource/Category:Pyrimidines +
, http://dbpedia.org/resource/Zolpidem +
|
| http://dbpedia.org/property/atcPrefix
|
N05
|
| http://dbpedia.org/property/atcSuffix
|
CM21
|
| http://dbpedia.org/property/bioavailability
|
Good
|
| http://dbpedia.org/property/c
|
22
|
| http://dbpedia.org/property/casNumber
|
1369764
|
| http://dbpedia.org/property/chembl
|
3545367
|
| http://dbpedia.org/property/chemspiderid
|
34500836
|
| http://dbpedia.org/property/class
|
http://dbpedia.org/resource/Orexin_antagonist +
|
| http://dbpedia.org/property/dailymedid
|
Lemborexant
|
| http://dbpedia.org/property/drugbank
|
DB11951
|
| http://dbpedia.org/property/eliminationHalfLife
|
198000.0
|
| http://dbpedia.org/property/excretion
|
Urine: 29.1%
, Feces: 57.4%
|
| http://dbpedia.org/property/f
|
2
|
| http://dbpedia.org/property/h
|
20
|
| http://dbpedia.org/property/iupacName
|
-2
|
| http://dbpedia.org/property/iupharLigand
|
9302
|
| http://dbpedia.org/property/kegg
|
D11022
|
| http://dbpedia.org/property/legalAu
|
S4
|
| http://dbpedia.org/property/legalCa
|
Rx-only
|
| http://dbpedia.org/property/legalUs
|
Schedule IV
|
| http://dbpedia.org/property/metabolism
|
Liver
|
| http://dbpedia.org/property/metabolites
|
M10
|
| http://dbpedia.org/property/n
|
4
|
| http://dbpedia.org/property/o
|
2
|
| http://dbpedia.org/property/pregnancyAu
|
B3
|
| http://dbpedia.org/property/proteinBound
|
94.0
|
| http://dbpedia.org/property/pubchem
|
56944144
|
| http://dbpedia.org/property/routesOfAdministration
|
http://dbpedia.org/resource/Oral_administration +
|
| http://dbpedia.org/property/smiles
|
CC1=NCC
|
| http://dbpedia.org/property/stdinchi
|
1
|
| http://dbpedia.org/property/stdinchikey
|
MUGXRYIUWFITCP-PGRDOPGGSA-N
|
| http://dbpedia.org/property/synonyms
|
E-2006
|
| http://dbpedia.org/property/tradename
|
Dayvigo
|
| http://dbpedia.org/property/unii
|
0
|
| http://dbpedia.org/property/width
|
250
|
| http://dbpedia.org/property/wikiPageUsesTemplate
|
http://dbpedia.org/resource/Template:Reflist +
, http://dbpedia.org/resource/Template:Portal_bar +
, http://dbpedia.org/resource/Template:Abbr +
, http://dbpedia.org/resource/Template:Nbsp +
, http://dbpedia.org/resource/Template:Cite_web +
, http://dbpedia.org/resource/Template:Insomnia_pharmacotherapies +
, http://dbpedia.org/resource/Template:Short_description +
, http://dbpedia.org/resource/Template:Drugbox +
, http://dbpedia.org/resource/Template:Orexin_receptor_modulators +
, http://dbpedia.org/resource/Template:Abbrlink +
, http://dbpedia.org/resource/Template:Hypnotics_and_sedatives +
, http://dbpedia.org/resource/Template:Use_dmy_dates +
, http://dbpedia.org/resource/Template:TOC_limit +
|
| http://purl.org/dc/terms/subject
|
http://dbpedia.org/resource/Category:Pyridines +
, http://dbpedia.org/resource/Category:Cyclopropanes +
, http://dbpedia.org/resource/Category:Japanese_inventions +
, http://dbpedia.org/resource/Category:Organofluorides +
, http://dbpedia.org/resource/Category:Orexin_antagonists +
, http://dbpedia.org/resource/Category:Fluoroarenes +
, http://dbpedia.org/resource/Category:Hypnotics +
, http://dbpedia.org/resource/Category:Carboxamides +
, http://dbpedia.org/resource/Category:Pyrimidines +
|
| http://purl.org/linguistics/gold/hypernym
|
http://dbpedia.org/resource/Antagonist +
|
| http://www.w3.org/ns/prov#wasDerivedFrom
|
http://en.wikipedia.org/wiki/Lemborexant?oldid=1105949600&ns=0 +
|
| http://xmlns.com/foaf/0.1/depiction
|
http://commons.wikimedia.org/wiki/Special:FilePath/Peak_normalized-concentrations_of_suvorexant_and_lemborexant_with_administration_at_steady_state_in_humans.png +
, http://commons.wikimedia.org/wiki/Special:FilePath/Lemborexant_Structure.svg +
|
| http://xmlns.com/foaf/0.1/isPrimaryTopicOf
|
http://en.wikipedia.org/wiki/Lemborexant +
|
| owl:sameAs |
http://ja.dbpedia.org/resource/%E3%83%AC%E3%83%B3%E3%83%9C%E3%83%AC%E3%82%AD%E3%82%B5%E3%83%B3%E3%83%88 +
, http://yago-knowledge.org/resource/Lemborexant +
, http://dbpedia.org/resource/Lemborexant +
, https://global.dbpedia.org/id/xd37 +
, http://rdf.freebase.com/ns/m.0138xv0p +
, http://pt.dbpedia.org/resource/Lemborexant +
, http://de.dbpedia.org/resource/Lemborexant +
, http://www.wikidata.org/entity/Q20707990 +
, http://vi.dbpedia.org/resource/Lemborexant +
, http://ru.dbpedia.org/resource/%D0%9B%D0%B5%D0%BC%D0%B1%D0%BE%D1%80%D0%B5%D0%BA%D1%81%D0%B0%D0%BD%D1%82 +
|
| rdf:type |
http://dbpedia.org/ontology/Drug +
, http://dbpedia.org/ontology/ChemicalSubstance +
, http://www.ontologydesignpatterns.org/ont/dul/DUL.owl#ChemicalObject +
, http://www.wikidata.org/entity/Q8386 +
|
| rdfs:comment |
Лемборексант — антагонист орексиновых рецепторов, используемый как снотворное средство. Одобрен для применения: США (2019), Япония (2020).
, Lemborexant, comercializado sob o nome com … Lemborexant, comercializado sob o nome comercial Dayvigo, é um medicamento antagonista da orexina utilizado no tratamento da insônia. É indicado especificamente para o tratamento da insônia caracterizada pela dificuldade de iniciar e/ou manter o sono em adultos. A medicação é tomada por via oral. Os efeitos colaterais do lemborexant incluem sonolência, fadiga, dor de cabeça e sonhos anormais. O medicamento é um duplo antagonista dos receptores de orexina (DORA). Atua como um antagonista dual e dos e . O lemborexant tem uma meia-vida longa de 17 a 55 horas e um atinge o pico de concentração em cerca de 1 a 3 horas. Não é um benzodiazepínico nem uma droga Z e, também, não interage com os receptores GABA, tendo um mecanismo de ação distinto.GABA, tendo um mecanismo de ação distinto.
, レンボレキサント（Lemborexant）は、成人の入眠困難および睡眠維持困難を特徴とする不眠症の治療薬である。レンボレキサントは、2019年12月20日に不眠症の成人による使用がアメリカ合衆国で承認され、2020年1月23日には日本での使用が承認され、エーザイから商品名「デエビゴ」で発売されている。
, Lemborexant, sold under the brand name Day … Lemborexant, sold under the brand name Dayvigo, is an orexin antagonist medication which is used in the treatment of insomnia. It is indicated specifically for the treatment of insomnia characterized by difficulties with sleep onset and/or maintenance in adults. The medication is taken by mouth. Lemborexant was approved for medical use in the United States in December 2019. It is a schedule IV controlled substance in the United States and may have a low potential for misuse. Besides lemborexant, other orexin receptor antagonists including suvorexant and daridorexant have also been introduced.nd daridorexant have also been introduced.
, Lemborexant ist ein Arzneistoff zur Behandlung von Schlafstörungen. Lemborexant wurde von Eisai entwickelt und im Jahr 2019 unter dem Handelsnamen Dayvigo von der FDA zugelassen.
|
| rdfs:label |
Lemborexant
, Лемборексант
, レンボレキサント
|
